Mathew S - Search Results

1

Exploratory genome-wide association analysis of response to ketamine and a polygenic analysis of response to scopolamine in depression.

Guo W, Machado-Vieira R, Mathew S, Murrough JW, Charney DS, Grunebaum M, Oquendo MA, Kadriu B, Akula N, Henter I, Yuan P, Merikangas K, Drevets W, Furey M, Mann JJ, McMahon FJ, Zarate CA Jr, Shugart YY. Guo W, et al. Among authors: mathew s. Transl Psychiatry. 2018 Dec 14;8(1):280. doi: 10.1038/s41398-018-0311-7. Transl Psychiatry. 2018. PMID: 30552317 Free PMC article.

2

Cerebrospinal fluid concentrations of biogenic amines and corticotropin-releasing factor in adolescent non-human primates as a function of the timing of adverse early rearing.

Mathew SJ, Coplan JD, Smith EL, Scharf BA, Owens MJ, Nemeroff CB, Mann JJ, Gorman JM, Rosenblum LA. Mathew SJ, et al. Stress. 2002 Sep;5(3):185-93. doi: 10.1080/1025389021000010521. Stress. 2002. PMID: 12186681

3

Differentiating depressed adolescent 24 h cortisol secretion in light of their adult clinical outcome.

Mathew SJ, Coplan JD, Goetz RR, Feder A, Greenwald S, Dahl RE, Ryan ND, Mann JJ, Weissman MM. Mathew SJ, et al. Neuropsychopharmacology. 2003 Jul;28(7):1336-43. doi: 10.1038/sj.npp.1300184. Epub 2003 Apr 30. Neuropsychopharmacology. 2003. PMID: 12784120

4

Open-label trial of riluzole in generalized anxiety disorder.

Mathew SJ, Amiel JM, Coplan JD, Fitterling HA, Sackeim HA, Gorman JM. Mathew SJ, et al. Am J Psychiatry. 2005 Dec;162(12):2379-81. doi: 10.1176/appi.ajp.162.12.2379. Am J Psychiatry. 2005. PMID: 16330605 Clinical Trial.

5

Neurobiology of anxiety disorders and implications for treatment.

Garakani A, Mathew SJ, Charney DS. Garakani A, et al. Among authors: mathew sj. Mt Sinai J Med. 2006 Nov;73(7):941-9. Mt Sinai J Med. 2006. PMID: 17195879 Review.

6

Hippocampal N-acetylaspartate concentration and response to riluzole in generalized anxiety disorder.

Mathew SJ, Price RB, Mao X, Smith EL, Coplan JD, Charney DS, Shungu DC. Mathew SJ, et al. Biol Psychiatry. 2008 May 1;63(9):891-8. doi: 10.1016/j.biopsych.2007.09.012. Epub 2007 Oct 29. Biol Psychiatry. 2008. PMID: 18028881 Free PMC article. Clinical Trial.

7

Novel drugs and therapeutic targets for severe mood disorders.

Mathew SJ, Manji HK, Charney DS. Mathew SJ, et al. Neuropsychopharmacology. 2008 Aug;33(9):2080-92. doi: 10.1038/sj.npp.1301652. Epub 2008 Jan 2. Neuropsychopharmacology. 2008. PMID: 18172433 Review.

8

Recent advances in the neurobiology of anxiety disorders: implications for novel therapeutics.

Mathew SJ, Price RB, Charney DS. Mathew SJ, et al. Am J Med Genet C Semin Med Genet. 2008 May 15;148C(2):89-98. doi: 10.1002/ajmg.c.30172. Am J Med Genet C Semin Med Genet. 2008. PMID: 18412102 Review.

9

Anxiety and depression: leading edge of therapy.

Mathew S, Charney D. Mathew S, et al. Mt Sinai J Med. 2008 May-Jun;75(3):171-3. doi: 10.1002/msj.20049. Mt Sinai J Med. 2008. PMID: 18704975 No abstract available.

10

Amino acid neurotransmitters assessed by proton magnetic resonance spectroscopy: relationship to treatment resistance in major depressive disorder.

Price RB, Shungu DC, Mao X, Nestadt P, Kelly C, Collins KA, Murrough JW, Charney DS, Mathew SJ. Price RB, et al. Among authors: mathew sj. Biol Psychiatry. 2009 May 1;65(9):792-800. doi: 10.1016/j.biopsych.2008.10.025. Epub 2008 Dec 5. Biol Psychiatry. 2009. PMID: 19058788 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,646 results

Search Page